Dlin-MC3-DMA: Ionizable Cationic Liposome for Potent siRNA and mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is a benchmark ionizable cationic lipid used in lipid nanoparticle (LNP) formulations for efficient in vivo delivery of siRNA and mRNA therapeutics. It is a key component in clinically validated LNPs, displaying up to 1000-fold higher gene silencing potency versus precursor lipids at doses as low as 0.005 mg/kg in mice. The ionizable nature of Dlin-MC3-DMA enables pH-dependent charge switching, facilitating endosomal escape while minimizing systemic toxicity. Recent machine learning-assisted studies have confirmed its superior performance in immunomodulatory mRNA delivery, particularly in neuroinflammatory and hepatic applications (Rafiei et al., 2025). Dlin-MC3-DMA’s solubility profile and storage requirements are critical for reproducible LNP formulation and therapeutic efficacy. For more, see the product dossier (A8791 kit).

Biological Rationale

Dlin-MC3-DMA is designed for nucleic acid delivery, addressing key challenges in systemic administration of siRNA and mRNA. Unmodified nucleic acids are rapidly degraded by nucleases and cleared from circulation. Cationic lipids, such as Dlin-MC3-DMA, condense nucleic acids and shield them from enzymatic degradation. The ionizable property allows for efficient encapsulation at acidic pH and minimal charge at physiological pH, reducing cytotoxicity and nonspecific interactions (Rafiei et al., 2025). This design principle supports efficient delivery to hepatocytes, immune cells, and other tissues. Compared to permanently cationic lipids, Dlin-MC3-DMA provides enhanced biocompatibility and improved endosomal escape, both essential for therapeutic efficacy. Over the past decade, it has become the gold standard for mRNA vaccine and siRNA gene silencing platforms (compare to earlier guidance).

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA functions as an ionizable cationic lipid within the LNP core. At acidic pH (≤5.5, typical of endosomes), its tertiary amine headgroup becomes protonated, acquiring a positive charge. This promotes electrostatic interaction with the negatively charged endosomal membrane, destabilizing the bilayer and facilitating endosomal escape of the encapsulated nucleic acid. At physiological pH (~7.4), Dlin-MC3-DMA is mostly uncharged, minimizing toxicity and off-target effects. LNPs containing Dlin-MC3-DMA are typically formulated with helper lipids (DSPC), cholesterol, and PEGylated lipids for colloidal stability. This composition enhances circulation time and tissue-specific delivery. In vivo, Dlin-MC3-DMA-containing LNPs have demonstrated efficient hepatic delivery and immunomodulatory effects in microglial applications (Rafiei et al., 2025).

Evidence & Benchmarks

• Dlin-MC3-DMA enables potent hepatic gene silencing, with an ED50 of 0.005 mg/kg (Factor VII, mouse model) and 0.03 mg/kg (TTR, non-human primates) (Table 2, Rafiei et al., 2025).
• In machine learning-optimized LNP formulations, Dlin-MC3-DMA supports robust mRNA transfection efficiency in both murine and human-derived microglia, enabling phenotype shifts from pro-inflammatory to anti-inflammatory states (Rafiei et al., 2025).
• Dlin-MC3-DMA-based LNPs show ~1000-fold greater silencing potency than DLin-DMA, its structural precursor, under identical formulation conditions (see mechanistic update).
• The solubility of Dlin-MC3-DMA in ethanol is ≥152.6 mg/mL, while it is insoluble in water and DMSO, enabling high concentration stock preparation for LNP assembly (A8791 kit).
• The optimal LNP composition for mRNA delivery typically includes Dlin-MC3-DMA, DSPC, cholesterol, and PEG-DMG in a molar ratio of approximately 50:10:38.5:1.5 (formulation review).

Applications, Limits & Misconceptions

Applications:

• Hepatic gene silencing: Dlin-MC3-DMA is validated for siRNA-mediated silencing of liver targets such as Factor VII and transthyretin (TTR) (Rafiei et al., 2025).
• mRNA vaccine and immunomodulatory delivery: LNPs with Dlin-MC3-DMA have supported COVID-19 mRNA vaccines and are under investigation for neuroinflammatory and cancer immunochemotherapy indications.
• Machine learning-guided optimization: Recent studies leverage ML to fine-tune LNP compositions for cell type-specific transfection, with Dlin-MC3-DMA as a core lipid (Rafiei et al., 2025).

Limits:

• Not suitable for hydrophobic or non-nucleic acid payloads due to charge and encapsulation constraints.
• Formulation efficacy is reduced if Dlin-MC3-DMA is used in aqueous or DMSO-based systems due to its insolubility.

For a mechanistic discussion of design trade-offs and predictive modeling, see this article, which this overview extends by focusing on clinical benchmarks and workflow parameters.

Common Pitfalls or Misconceptions

• Dlin-MC3-DMA is not permanently cationic: It is nearly neutral at physiological pH, limiting off-target effects—unlike traditional cationic lipids.
• Solubility limitations: Attempting to dissolve Dlin-MC3-DMA in water or DMSO leads to phase separation and formulation failure.
• Storage constraints: Solutions should be stored at -20°C or below and used promptly; prolonged storage at room temperature degrades activity.
• Non-generalizability to all cell types: While optimal in hepatic and microglial systems, Dlin-MC3-DMA-based LNPs may require redesign for efficient delivery to other tissues.
• Misinterpretation of machine learning predictions: ML-optimized LNPs are validated for specific activation states (e.g., LPS-activated microglia) but are less predictive for others (e.g., IL4/IL13-activated) (Rafiei et al., 2025, Table S3).

Workflow Integration & Parameters

For optimal results, Dlin-MC3-DMA must be dissolved in ethanol to prepare concentrated stock solutions (≥152.6 mg/mL). LNPs are typically assembled by rapid mixing of the lipid ethanol phase with an aqueous nucleic acid solution under controlled microfluidic or bulk mixing conditions. Helper lipids (DSPC), cholesterol, and PEG-DMG are included for structural integrity and pharmacokinetic tuning. The final LNP formulation is dialyzed or subjected to tangential flow filtration to remove ethanol and unencapsulated payload. Storage of LNPs at 4°C is recommended for short-term use (<1 week); for longer-term, aliquots should be stored at -80°C. Dlin-MC3-DMA is highly sensitive to hydrolysis and oxidation; solutions must be used promptly. For detailed workflow parameters, the A8791 kit provides validated protocols. For troubleshooting and advanced design, see this review, which this article updates by specifying machine learning-guided composition preferences and new stability data.

Conclusion & Outlook

Dlin-MC3-DMA has established itself as the preferred ionizable cationic lipid for LNP-mediated siRNA and mRNA delivery, driving both basic research and clinical translation in gene silencing and immunomodulatory therapies. Robust, machine learning-assisted optimization continues to extend its utility to new cell types and disease models. Future developments are expected to further refine Dlin-MC3-DMA formulations for precision delivery, reduced immunogenicity, and expanded therapeutic windows. For product specifics, refer to the official site.